- Home
- LPX vs HALO Comparison
LPX vs HALO Comparison
Compare LPX & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPX
- HALO
- Stock Information
- Founded
- LPX 1973
- HALO 1998
- Country
- LPX United States
- HALO United States
- Employees
- LPX N/A
- HALO N/A
- Industry
- LPX Forest Products
- HALO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LPX Basic Materials
- HALO Health Care
- Exchange
- LPX Nasdaq
- HALO Nasdaq
- Market Cap
- LPX 6.2B
- HALO 7.4B
- IPO Year
- LPX N/A
- HALO N/A
- Fundamental
- Price
- LPX $86.61
- HALO $52.81
- Analyst Decision
- LPX Buy
- HALO Buy
- Analyst Count
- LPX 8
- HALO 9
- Target Price
- LPX $108.13
- HALO $63.56
- AVG Volume (30 Days)
- LPX 824.4K
- HALO 1.7M
- Earning Date
- LPX 08-06-2025
- HALO 08-05-2025
- Dividend Yield
- LPX 1.29%
- HALO N/A
- EPS Growth
- LPX 56.47
- HALO 55.40
- EPS
- LPX 5.71
- HALO 3.76
- Revenue
- LPX $2,941,000,000.00
- HALO $1,084,306,000.00
- Revenue This Year
- LPX N/A
- HALO $25.77
- Revenue Next Year
- LPX $7.00
- HALO $18.01
- P/E Ratio
- LPX $15.22
- HALO $14.04
- Revenue Growth
- LPX 8.09
- HALO 25.64
- 52 Week Low
- LPX $78.82
- HALO $42.01
- 52 Week High
- LPX $122.87
- HALO $70.51
- Technical
- Relative Strength Index (RSI)
- LPX 40.15
- HALO 41.21
- Support Level
- LPX $85.34
- HALO $53.54
- Resistance Level
- LPX $90.01
- HALO $55.60
- Average True Range (ATR)
- LPX 2.36
- HALO 1.24
- MACD
- LPX -0.63
- HALO 0.09
- Stochastic Oscillator
- LPX 15.68
- HALO 4.62
About LPX Louisiana-Pacific Corporation
Louisiana-Pacific is primarily an oriented strand board producer and also offers engineered wood siding used in home construction and repair and remodel projects. The company is largely exposed to the North American housing market but has also established capacity in Brazil and Chile.
About HALO Halozyme Therapeutics Inc.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.